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MaOBJECTIVES This study sought to investigate the efﬁcacy of prasugrel compared with clopidogrel in clopidogrel
nonresponders.
BACKGROUND Clopidogrel nonresponsiveness is a strong marker of the risk of cardiac death and stent thrombosis
after a percutaneous coronary intervention (PCI). It is unknown whether clopidogrel nonresponsiveness is a nonmodiﬁ-
able risk factor or whether prasugrel with more potent and predictable platelet inhibition as measured by ex vivo
techniques is associated with a positive effect on clinical outcome.
METHODS The RECLOSE-3 (REsponsiveness to CLOpidogrel and StEnt thrombosis) study screened clopidogrel nonre-
sponders after a 600-mg loading dose of clopidogrel. Clopidogrel nonresponders switched to prasugrel (10 mg/day) the
day of the PCI, and an adenosine diphosphate (ADP) test (10 mmol/l of ADP) was performed 6 days after the PCI. The
primary endpoint was 2-year cardiac mortality. Patient outcome was compared with the RECLOSE-2–ACS study.
RESULTS We screened 1,550 patients, of whom 302 were clopidogrel nonresponders. The result of the ADP test was
77.6  6.2%. After switching to prasugrel, the ADP test result decreased to 47.1  16.8%. The 2-year cardiac mortality
rate was 4% in the RECLOSE-3 study and 9.7% in nonresponders of the RECLOSE-2–ACS study (p ¼ 0.007). The deﬁnite
and probable stent thrombosis rates were 0.7% and 4.4%, respectively (p ¼ 0.004). On multivariable analysis, prasugrel
treatment was related to the risk of 2-year cardiac death (hazard ratio: 0.32, p ¼ 0.036).
CONCLUSIONS Clopidogrel nonresponsiveness can be overcome by prasugrel (10 mg/day), and optimal platelet ag-
gregation inhibition on prasugrel treatment is associated with a low rate of long-term cardiac mortality and stent
thrombosis. (J Am Coll Cardiol Intv 2015;8:1563–70) © 2015 by the American College of Cardiology Foundation.S everal studies have shown that high residualplatelet reactivity while on clopidogrel treat-ment is a strong marker of the risk ischemic
events in patients undergoing percutaneous coronary
intervention (PCI) (1–16). Prasugrel in clopidogrel
nonresponders is effective in providing platelet
aggregation inhibition in most patients (17). No
evidence exists showing that the achievement of
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ABBR EV I A T I ON S
AND ACRONYMS
ACS = acute coronary
syndrome(s)
ADP = adenosine diphosphate
CI = conﬁdence interval
HR = hazard ratio
MI = myocardial infarction
PCI = percutaneous coronary
intervention
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1564The RECLOSE-3 (REsponsiveness to CLO-
pidogrel and StEnt thrombosis) study sought
to determine the efﬁcacy of prasugrel treat-
ment in clopidogrel nonresponders under-
going a PCI.
METHODS
PATIENT SELECTION AND INTERVENTIONS.
From April 2010 to December 2012, consecu-
tive patients undergoing PCI were screenedfor nonresponsiveness to clopidogrel using a loading
dose of 600 mg of clopidogrel and assessing platelet
reactivity with light transmittance aggregometry.SEE PAGE 1571There were no exclusion criteria except current
treatment with prasugrel. All patients with high re-
sidual platelet reactivity were switched to prasugrel
(10 mg/day or 5 mg in patients older than 75 years of
age or with a history of stroke if the adenosine
diphosphate [ADP] test result was <70%) the same
day of the PCI. All patients underwent drug-eluting
stent implantation, and the PCI was performed us-
ing standard techniques. Dual antiplatelet treatment
was prescribed for at least 6 months. Because of the
nonrandomized study design, the clinical outcome of
clopidogrel nonresponders who switched to prasugrel
was compared with that of the historical cohort of
clopidogrel nonresponders in the RECLOSE-2–ACS
(n ¼ 248) study. Details of this study were pre-
viously reported (15). Brieﬂy, the RECLOSE-2–ACS
study enrolled 1,789 patients with acute coronary
syndromes (ACS) and treated with PCI, of whom
248 were clopidogrel nonresponders. Clopidogrel
nonresponders had an increased long-term dose of
clopidogrel (150 to 300 mg/day) or switched to ticlo-
pidine (500 to 1,000 mg/day) under ADP test results
guidance, with the goal of reaching an ADP test result
of <70% platelet aggregation. The primary endpoint
was a composite of cardiac death, myocardial infarc-
tion, any urgent coronary revascularization, and
stroke at 2-year follow-up. Secondary endpoints were
stent thrombosis and each component of the primary
endpoint. The 2-year cardiac mortality rate was 9.7%
in clopidogrel nonresponders and 4.3% in clopidogrel
responders, and the clopidogrel nonresponsiveness
was independently associated with the risk of 2-year
cardiac death (hazard ratio [HR] compared with
clopidogrel responders (HR: 1.81; 95% conﬁdence
interval [CI]: 1.18 to 2.76; p ¼ 0.006) (15).
PLATELET REACTIVITY ASSESSMENT. Blood sam-
ples anticoagulated with 0.129 mol/l sodium citrate
(9:1 ratio) for platelet reactivity assessment wasobtained at least 12 h after clopidogrel loading and
6 days after the PCI while the patient was on pra-
sugrel treatment. Platelet-rich plasma, obtained by
centrifuging whole blood for 10 min at 200g, was
stimulated with 10 mmol/l of ADP (Mascia Brunelli,
Milan, Italy) and residual aggregation was assessed
using an APACT 4 light transmittance aggregometer
(Helena Laboratories, Milan, Italy). The 100% line
was set using platelet-poor plasma and the 0 base-
line established with platelet-rich plasma (adjusted
from 18  109/l up to 30 109/l). Platelet aggregation
(according to the Born method) was evaluated
considering the maximal percentage of platelet ag-
gregation in response to stimulus. High residual
platelet reactivity was deﬁned as platelet aggrega-
tion by ADP $70% (5,10–13).
FOLLOW-UP. All patients had scheduled examina-
tions at 1, 6, 12, and 24 months. All other possible
information derived from hospital readmission or by
the referring physician, relatives, or municipality live
registries was entered into the prospective database.
ENDPOINTS. The primary endpoint of the study was
the 2-year cardiac mortality. Secondary endpoints
were: 1) myocardial infarction (MI); 2) ischemic
stroke; 3) composite of cardiac death and MI, 4) stent
thrombosis; 5) major bleeding; and 6) degree of pla-
telet aggregation inhibition as assessed by light
transmittance aggregometry. All deaths were consid-
ered cardiac unless an unequivocal noncardiac cause
could be documented. The diagnosis of non–Q-wave
MI was on the basis of an increase in creatine kinase–
myocardial band isoenzyme or troponin I >3 times the
upper limit of normal or for patients with elevated
values on admission, as a re-elevation of creatine ki-
nase–myocardial band or troponin I values. A Q-wave
MI was deﬁned as the development of new Q waves in
2 or more electrocardiographic leads, and in addition
to creatine kinase–myocardial band or troponin I
elevation. Ischemic stroke was deﬁned as an acute
neurological defect lasting more than 24 h without
computed tomography evidence of bleeding. Stent
thrombosis was deﬁned according to the Academic
Research Consortium criteria (19). Major bleeding was
deﬁned according to the Thrombolysis In Myocardial
Infarction-38 criteria (20).
The study was approved by the institutional review
committee of Careggi Hospital, and all patients gave
written informed consent to participate in the study
and undergo PCI.
STATISTICAL ANALYSIS. In the RECLOSE-3 study,
the statistical hypothesis assumed a decrease of 50%
in 2-year cardiac mortality in patients switched to
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1565prasugrel compared with clopidogrel nonresponders
of the RECLOSE-2–ACS study. According to this hy-
pothesis, statistical power was >80% on the basis of a
maximal sample size of 500 patients for the primary
endpoint. Discrete data were summarized as fre-
quencies, and continuous data were expressed as
mean  SD or median and interquartile range, as
appropriate. The chi-square test was used for com-
parison of categorical variables, and the unpaired
2-tailed Student t test or Mann-Whitney rank sum
test was used to test differences among continuous
variables. Survival curves were generated using the
Kaplan-Meier method, and the difference between
groups was assessed by the log-rank test. A multi-
variable Cox proportional hazards model was per-
formed to evaluate the independent contribution of
clinical, angiographic, and procedural variables to
the primary endpoint of cardiac mortality. Variables
known to be related to prognostic outcome or vari-
ables with a p value <0.05 on Cox univariate anal-
ysis were forced into the ﬁnal multivariate model.
The following variables were tested: age 75 years
and older, sex, body mass index $30 kg/m2, smoking,
diabetes mellitus, hypertension, hypercholesterole-
mia, history of MI, ACS on admission, serum creatinineFIGURE 1 Flow Chart of the RECLOSE-2–ACS and RECLOSE-3 Studies
RECLOSE ¼ Responsiveness to CLOpidogrel and StEnt Thrombosis.level >1.50 mg/dl, left ventricular ejection fraction
<40%, 3-vessel coronary disease, implanted drug-
eluting stent, and prasugrel treatment. The propor-
tional hazard assumption was assessed and satisﬁed
graphically by plotting log (log) survival curves
against log survival time for each predictor category
and verifying whether curves were parallel, and,
in addition, using time-dependent covariates. All
tests were 2-sided, and a p value <0.05 was consid-
ered signiﬁcant. Analyses were performed using
the software package SPSS version 19 (SPSS Inc., Chi-
cago, Illinois).
RESULTS
We screened 1,550 patients after administering a
600-mg loading dose of clopidogrel. Of these, 302
patients had a residual platelet reactivity >70% on
the ADP test and were switched to prasugrel treat-
ment. This patient cohort was compared with that of
the RECLOSE-2–ACS study that included 248 clopi-
dogrel nonresponders (Figure 1). Table 1 summarizes
the baseline clinical characteristics of the 2 groups.
Nonresponders in the RECLOSE-3 had a higher inci-
dence of hypertension, a history of MI, a history of
TABLE 1 Baseline Clinical Characteristics
Total
(N ¼ 550)
RECLOSE 2-ACS
(n ¼ 248)
RECLOSE-3
(n ¼ 302) p Value
Age, yrs 71.8  11.1 71.7  11.3 71.9  10.9 0.795
Age $75 yrs 264 (48) 127 (51) 137 (45) 0.174
Men 421 (76) 191 (77) 230 (76) 0.813
Hypercholestherolemia 313 (57) 134 (54) 179 (59) 0.217
Hypertension 366 (57) 151 (61) 215 (71) 0.011
Smokers 124 (22) 48 (19) 76 (25) 0.105
Body mass index, kg/m2 26.5  3.7 26.6  3.9 26.4  3.7 0.849
Diabetes mellitus 162 (29) 70 (28) 92 (30) 0.567
History of PCI 188 (34) 47 (19) 141 (48) <0.001
History of coronary surgery 45 (8.2) 16 (6.5) 29 (9.6) 0.180
History of myocardial infarction 189 (34) 70 (28) 119 (39) 0.006
Creatinine >1.50 mg/dl 77 (14) 28 (11) 49 (16) 0.097
LVEF #40% 168 (30) 97 (39) 71 (23) <0.001
ACS on admission 374 (68) 248 (100) 126 (42) <0.001
STEMI 98 (18) 82 (33) 16 (5.3) <0.001
Unstable angina/non-STEMI 276 (50) 166 (67) 110 (36) <0.001
ADP test after clopidogrel LD
77.6  6.5 77.6  6.8 77.6  6.2 0.992
76 (72–81) 76 (72–81) 76 (73–82) 0.606
ADP test after treatment adjustment or switch to prasugrel
53.6  18.1 63.6  15.2 47.1  16.8 <0.001
56 (40–67) 64 (54–75) 47 (34–62) <0.001
ADP test in ACS patients (N ¼ 374) (n ¼ 248) (n ¼ 126)
After clopidogrel LD
77.7  6.5 77.6  6.8 78.0  5.8 0.554
76 (73–81) 76 (72–81) 77 (73–82) 0.173
After treatment adjustment or switch to prasugrel
58.3  16.5 63.6  15.2 50.0  15.2 <0.001
60 (47–71) 64 (54–75) 48 (39–62) <0.001
ADP test in non-ACS patients (n ¼ 176)
After clopidogrel LD
77.3  6.4
76 (72–82)
After switch to prasugrel
45.1  17.6
45 (31–62)
Values are mean  SD, n (%), or median (interquartile range).
ACS ¼ acute coronary syndrome; ADP ¼ adenosine diphosphate; LD ¼ loading dose; LVEF ¼ left ventricular ejection fraction; MI ¼myocardial infarction; PCI ¼ percutaneous
coronary intervention; STEMI ¼ ST-segment elevation myocardial infarction.
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1566PCI, and better left ventricular function than the
RECLOSE-2–ACS nonresponders. The clinical pres-
entation was an ACS in 42% of patients of the
RECLOSE-3, whereas all patients in the RECLOSE-2–
ACS had an ACS on admission. The ADP test results
after 600-mg loading dose of clopidogrel was
administered were nearly identical in the 2 groups
(77.6  6.2% in the RECLOSE-3, and 77.6  6.8% in
the RECLOSE-2–ACS, p ¼ 0.992). Overall, the ADP
test result decreased to 47.1  16.8% after switching
to prasugrel (p < 0.001), and only 26 patients had
a residual platelet reactivity >70% (mean value,
73.9  3.8%).Table 2 shows the angiographic and procedural
characteristics of the 2 groups. The RECLOSE-3 group
showed a trend toward more 3-vessel PCIs and un-
protected left main PCIs than the RECLOSE-2–ACS
group. The number of stents and the total stent
length per patient were higher in the RECLOSE-3
cohort and almost all patients (91%) received drug-
eluting stents. At discharge, RECLOSE-3 patients
were prescribed aspirin and proton pump inhibitors
less frequently than the RECLOSE-2–ACS patients.
Table 3 summarizes the 2-year clinical outcome
(follow-up rate: 99.8%). Themedian follow-up lengthwas
961 days (interquartile range [IQR]: 786 to 1,260 days).
TABLE 3 2-Year Clinical Outcome
RECLOSE-
2–ACS
(n ¼ 247)
RECLOSE-3
(n ¼ 302) p Value
Cardiac death 24 (9.7) 12 (4.0) 0.007
Myocardial infarction 8 (3.2) 8 (2.6) 0.683
Stroke 3 (1.2) 2 (0.7) 0.498
Cardiac death and myocardial
infarction
32 (13) 20 (6.6) 0.012
Stent thrombosis 15 (6.1) 8 (2.6) 0.046
Deﬁnite 7 (2.8) 2 (0.7) 0.046
Probable 4 (1.6) 0 0.026
Possible 4 (1.6) 6 (2.0) 0.749
Major bleeding 0 3 (1.0) 0.116
Minor bleeding 3 (1.2) 16 (5.3) 0.009
ACS patients (n ¼ 247) (n ¼ 126)
Cardiac death 24 (9.7) 4 (3.2) 0.023
Myocardial infarction 8 (3.2) 6 (4.8) 0.464
Cardiac death and myocardial
infarction
32 (13) 10 (7.9) 0.147
Stent thrombosis 15 (6.1) 2 (1.6) 0.049
Deﬁnite/probable 11 (4.4) 1 (0.8) 0.058
Non-ACS patients (n ¼ 176)
Cardiac death 8 (4.5)
Myocardial infarction 2 (1.1)
Cardiac death and myocardial
infarction
10 (5.7)
Stent thrombosis 6 (3.4)
Deﬁnite/probable 1 (0.6)
Values are n (%).
ACS ¼ acute coronary syndrome.
TABLE 2 Angiographic and Intervention Characteristics
RECLOSE-2–ACS
(N ¼ 248)
RECLOSE-3
(N ¼ 302) p Value
Multivessel CAD 162 (65) 213 (70) 0.192
3-vessel CAD 82 (33) 115 (38) 0.222
3-vessel PCI 25 (10) 45 (15) 0.091
Treated vessel
LAD 145 (58) 181 (60) 0.728
RCA 96 (39) 124 (41) 0.576
Circumﬂex artery 94 (38) 105 (35) 0.446
Left main artery 22 (8.9) 43 (14) 0.052
Ramus 9 (3.6) 5 (1.7) 0.144
No. of stents per patient 1.9  1.1 2.4  1.4 <0.001
Total stent length, mm 36.0  26.5 50.5  36.0 <0.001
Drug-eluting stent 133 (54) 275 (91) <0.001
Aspirin at discharge 239 (96) 260 (86) <0.001
Warfarin at discharge 5 (2.0) 12 (4.0) 0.187
Proton pump inhibitor at discharge 169 (68) 178 (59) 0.026
Values are n (%) or mean  SD.
CAD ¼ coronary artery disease; LAD ¼ left anterior descending artery; PCI ¼ percutaneous
coronary intervention; RCA ¼ right coronary artery.
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1567At 1 year, 91% and 88% of the patients in the
RECLOSE-2–ACS and RECLOSE-3, respectively, were
receiving thienopyridine treatment, and the number
of patients had decreased to 68% and 21%, respec-
tively, at 2-year follow-up.
The 2-year cardiac mortality rate was 4.0% in
the RECLOSE-3 group and 9.7% in the RECLOSE-2–
ACS group (p ¼ 0.007). The difference in 2-year
cardiac mortality remained considering exclusively
patients with ACS on admission who accounted for
the major difference in baseline characteristics be-
tween groups: 3.2% and 9.7%, respectively (p ¼
0.023) (Table 3). The rates of composite of cardiac
death and MI and of deﬁnite and probable stent
thrombosis were lower in the RECLOSE-3 group
than in the RECLOSE-2–ACS cohort: 6.6% and
13.0% (p ¼ 0.012), and 0.7% and 4.4% (p ¼ 0.004),
respectively. The cardiac survival rate was 96  1%
in the RECLOSE-3 group and 90  2% in
the RECLOSE-2–ACS group (p ¼ 0.011) (Figure 2A).
Similarly, the survival rate of freedom from cardiac
death and MI was 93  1% in the RECLOSE-3 group
and 87  2% in the RECLOSE-2–ACS group
(p ¼ 0.025) (Figure 2B). On the ﬁnal model of
multivariable analysis, prasugrel treatment was
inversely related to the risk of 2-year cardiac death
(HR: 0.32, 95% CI: 0.11 to 0.92, p ¼ 0.036); the
other variables signiﬁcantly related to the risk of
cardiac death were age 75 years and older (HR:
2.89, 95% CI: 1.34 to 6.23, p ¼ 0.007) and renal
insufﬁciency (HR: 2.35, 95% CI: 1.12 to 4.95,
p ¼ 0.024), whereas left ventricular ejection
fraction <40% (HR: 1.63, 95% CI: 0.83 to 3.21, p ¼
0.155) and ACS (HR: 0.56, 95% CI: 0.17 to 1.88, p ¼
0.345) were not related to the primary endpoint.
There were no differences in major bleeding rates,
whereas the minor bleeding rate was higher in the
RECLOSE-3 group (Table 3).
DISCUSSION
The main ﬁnding of the RECLOSE-3 study is that
nonresponsiveness to clopidogrel is a modiﬁable
risk factor for cardiac death after PCI. The RECLOSE-3
shows that clopidogrel nonresponders switching
to prasugrel treatment is associated with a 2-year
cardiac mortality rate nearly identical to the popu-
lation of clopidogrel responders in the RECLOSE-2–
ACS: 4% and 4.3%, respectively. Moreover, the rates
of deﬁnite or probable stent thrombosis were lower
in the RECLOSE-3 group than in the RECLOSE-2–
ACS group (0.7% and 4.4%, respectively, p ¼
0.004).
FIGURE 2 Survival Analyses of Clopidogrel Nonresponders in RECLOSE-2–ACS and RECLOSE-3 Studies
(A) Two-year cardiac survival analysis of clopidogrel nonresponders in the RECLOSE-2–ACS and RECLOSE-3 studies. (B) Two-year survival
analysis of freedom from cardiac death and myocardial infarction (MI) in clopidogrel nonresponders in the RECLOSE-2–ACS and RECLOSE-3
studies.
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1568Two previous studies, the GRAVITAS (Gauging
Responsiveness With A VerifyNow Assay–Impact on
Thrombosis And Safety) (21) and the RECLOSE-2–ACS
(15), tried to overcome clopidogrel resistance with an
increased dose of clopidogrel, which had some effect
on the platelet reactivity tests but without any sig-
niﬁcant impact on clinical outcome.
As shown by previous studies, prasugrel may
afford effective platelet aggregation inhibition in
most patients with high residual platelet reactivity on
clopidogrel treatment (17,18). In the RECLOSE-3, the
ADP test result decreased <50% in the majority of
patients, and all 26 patients with high residual
platelet reactivity on prasugrel treatment had an ADP
test result very close to the pre-speciﬁed cutoff of
70%. Similar effects on in vitro testing were revealed
in the TRIGGER-PCI trial, which is the only random-
ized trial that compared prasugrel with clopidogrel in
clopidogrel nonresponders (18). This TRIGGER-PCI
study could not demonstrate the efﬁcacy of the
strategy of switching to prasugrel in clopidogrel
nonresponders. The lack of demonstration of the
clinical efﬁcacy of switching to prasugrel in clopi-
dogrel nonresponders may be explained by the fact
that patients enrolled in the TRIGGER-PCI trial had a
short-term follow-up (6 months), very low risk of
events (stable coronary artery disease, single stent
implantation in the majority of patients, patients withperiprocedural complications were excluded), and
the sample size was too small to demonstrate any
signiﬁcant impact of prasugrel (of 212 patients ran-
domized to prasugrel, only 136 completed the study)
on clinical outcome (18).
STUDY LIMITATIONS. The RECLOSE-3 study has a
nonrandomized design and as such has the inherent
limitations of this type of study. However, several
strengths of the study should be outlined. In the
RECLOSE-3 study, consecutive patients were screened
without any restriction on the basis of age, clinical
presentation, or coronary anatomy complexity, and
this patient cohort may be considered representative
of the broad spectrum of patients with coronary artery
disease who are treated by PCI. Second, all patients
recruited in the study received the same loading dose
of clopidogrel, and platelet reactivity assessment was
made using light transmittance aggregometry and a
cutoff of the ADP test that have been validated in
thousands of patients. The comparison with the his-
torical cohort of the patients of the RECLOSE-2–ACS
study was made with appropriate statistical adjust-
ment to correct for differences between groups,
including in the model of multivariable analysis the
variables ACS and left ventricular ejection fraction
<40% that accounted for the major differences be-
tween the RECLOSE-2–ACS and RECLOSE-3 patient
PERSPECTIVES
WHAT IS KNOWN? Dual antiplatelet treatment is the standard
of care in patients undergoing PCI, and clopidogrel is still the more
used thienopyridine in current practice. Nonresponsiveness to clo-
pidogrel is a major pitfall of this adjunctive therapy and is associ-
ated with a very high risk of death and other thrombotic events.
WHAT IS NEW? Prasugrel treatment overcomes nonrespon-
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1569cohorts. The short time lag between the enrollment
of patients in the RECLOSE-2–ACS and RECLOSE-3
avoided the potential confounding effects of
possible advances in PCI and adjunctive pharma-
cological treatment. However, despite the appro-
priate statistical methods, we cannot exclude the
effect of untested confounding variables. Finally,
the aim of the study was to test the hypothesis
that nonresponsiveness to clopidogrel is a modiﬁ-
able risk factor and not the comparison of prasu-
grel with clopidogrel or other antiplatelet drugs in
clopidogrel nonresponders, and ethical issues make
the possibility of performing a randomized study
using clopidogrel in the control arm in clopidogrel
nonresponders unlikely.siveness to clopidogrel and results in a thrombotic risk similar to
that in clopidogrel responders.
WHAT IS NEXT? The results of this study should be considered
for further studies of tailored therapy using new antithrombotic
agents.CONCLUSIONS
Clopidogrel nonresponsiveness can be overcome by
prasugrel treatment. In clopidogrel nonresponders,
prasugrel therapy is associated with a high rate of
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